TABLE 1.
Studies and patients characteristics.
| Reference, year | Study design | N° patients included (total) | Treatment period | Diagnosis | Site (%) | T stage: 1–2 (%) | T stage: 3–4 (%) | cN1 (%) |
|---|---|---|---|---|---|---|---|---|
| Laughlin et al, 2022 27 | Retrosp. | 29 (65) | 1998–2019 | UR |
ECC: 90.0 HCCA: 10.0 |
64.0 | 36.0 | 38.0 |
| Koh et al, 2021 28 | Retrosp. | 61 (76) | 2001–2015 | LR |
ECC: 57.0 HCCA: 43.0 |
58.0 | 42.0 | 29.0 |
| Jethwa et al, 2020 10 | Retrosp. | 48 (48) | 1998–2018 | UR |
ECC: 85.0 GBC: 15.0 |
42.0 | 58.0 | 29.0 |
| Hung et al, 2020 11 | Retrosp. | 23 (30) | 2015–2017 | UR and LR |
ICC: 60.0 ECC: 30.0 GBC: 10.0 |
26.7 | 70.0 | 56.7 |
| Sebastian et al, 2019 29 | Retrosp. | 54 (141) | 2004–2014 | UR | NR | 51.9 | 48.1 | NR |
| Bisello et al, 2018 8 | Retrosp. | 61 (76) | 1991–2017 | UR and LR |
ICC: 3.9 HCCA: 51.3 ECC: 32.9 GBC: 3.9 LR: 7.8 |
21.5 | 78.5 | 36.8 |
| Verma et al, 2018 31 | Retrosp. | 666 (2842) | 2004–2013 | UR | ICC: 100.0 | NR | NR | NR |
| Verma et al, 2017 30 | Retrosp. | 327 (1199) | 2004–2013 | UR | GBC: 100.0 | 7.0 | 59.0 | 30.0 |
| Kim et al, 2017 15 | Retrosp. | 18 (23) | 2001–2013 | LR | ECC: 100.0 | 30.4 a | 69.6 a | 47.8 a |
| Jackson et al, 2016 32 | Retrosp. | 374 (1636) | 2001–2011 | UR | ICC: 100.0 | 28.6 b | 71.3 b | NR |
| Lee et al, 2016 21 | Prosp. | 18 (18) | 2007–2011 | UR |
ECC: 22.2 HCCA: 33.3 GBC: 44.5 |
22.2 b | 77.8 b | NR |
| Chen et al, 2015 22 | Retrosp. | 16 (34) | 2001–2010 | UR | HCCA: 100 | 31.0 | 69.0 | 50.0 |
| Phelip et al, 2014 23 |
Prosp. Phase II |
18 (34) | 2006–2010 | UR |
ICC: 56.0 ECC: 11.0 HCCA: 22.0 GBC: 11.0 |
NR | NR | NR |
| Moureau‐Zabotto et al, 2013 14 | Retrosp. | 18 (30) | 1995–2008 | UR and LR |
HCCA: 67.0 ECC: 33.3 b |
12.0 b | 75.0 b | 46.0 b |
| Yoshioka et al, 2014 25 | Retrosp. | 117 (498) | 2000–2011 | UR |
ICCA: 14.0 ECC: 35.0 HCC: 44.0 GBC: 8.0 a |
53.0 a | 32.0 a | NR |
| Yi et al, 2014 26 | Retrosp. | 106 (176) | 1995–2010 | UR |
ICC: 39.6 ECC: 29.2 GBC: 31.1 |
11.3 | 88.7 | 80.2 |
| Habermehl et al, 2012 24 | Retrosp. | 11 (25) | 2003–2010 | UR and LR |
ECC: 36.4 HCCA: 63.6 |
0.0 | 100.0 | 81.8 |
Abbreviations: BTC, biliary tract cancer; ECC, extrahepatic cholangiocarcinoma; GBC, gallbladder cancer; HCCA, hilar cholangiocarcinoma (Klatskin tumor); ICC, intrahepatic cholangiocarcinoma; LR, local recurrence; NR, not reported; UR, unresectable.
a
Related to the whole population included in the analysis;
b
Stage reported according to American Joint Committee on Cancer (AJCC) staging system.